Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. A pilot study.

Rifaximin effectively normalized the GHBT and reduced the IBS symptoms by possibly counteracting the SIBO. Whether such therapeutic approach is ultimately associated with symptom improvement in the long term, however, requires additional studies.